HK1184451A1 - 作為脯氨酰羥化酶抑制劑的 -氨基喹唑啉- -基- -吡唑- -羧酸化合物 - Google Patents
作為脯氨酰羥化酶抑制劑的 -氨基喹唑啉- -基- -吡唑- -羧酸化合物Info
- Publication number
- HK1184451A1 HK1184451A1 HK13111845.9A HK13111845A HK1184451A1 HK 1184451 A1 HK1184451 A1 HK 1184451A1 HK 13111845 A HK13111845 A HK 13111845A HK 1184451 A1 HK1184451 A1 HK 1184451A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrrazole
- aminoquinazolin
- carboxylic acid
- acid compounds
- prolyl hydroxylase
- Prior art date
Links
- -1 4 - aminoquinazolin- 2 - yl Chemical group 0.000 title 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 title 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37366410P | 2010-08-13 | 2010-08-13 | |
| PCT/US2011/047626 WO2012021830A1 (en) | 2010-08-13 | 2011-08-12 | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1184451A1 true HK1184451A1 (zh) | 2014-01-24 |
Family
ID=44533176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13111845.9A HK1184451A1 (zh) | 2010-08-13 | 2013-10-22 | 作為脯氨酰羥化酶抑制劑的 -氨基喹唑啉- -基- -吡唑- -羧酸化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US8796263B2 (zh) |
| EP (1) | EP2603502B1 (zh) |
| JP (1) | JP5755741B2 (zh) |
| CN (1) | CN103068821B (zh) |
| AU (1) | AU2011289230B2 (zh) |
| HK (1) | HK1184451A1 (zh) |
| WO (1) | WO2012021830A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013505899A (ja) | 2009-09-28 | 2013-02-21 | チールー ファーマシューティカル カンパニー、リミテッド | チロシンキナーゼ阻害剤として有用な４−（置換アニリノ）キナゾリン誘導体 |
| CN103068821B (zh) * | 2010-08-13 | 2015-02-25 | 詹森药业有限公司 | 作为脯氨酰羟化酶抑制剂的4-氨基喹唑啉-2-基-1-吡唑-4-羧酸化合物 |
| BR112014009910B1 (pt) | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica |
| AU2015311333B2 (en) | 2014-09-02 | 2017-11-16 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| ES2918589T3 (es) * | 2015-11-25 | 2022-07-19 | Convergene Llc | Inhibidores de bromodomios BET bicíclicos y usos de los mismos |
| US20230218592A1 (en) | 2020-04-20 | 2023-07-13 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2021222424A1 (en) * | 2020-04-29 | 2021-11-04 | BioAge Labs, Inc. | Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions |
| CN115943144A (zh) * | 2020-08-14 | 2023-04-07 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| WO2023064512A1 (en) * | 2021-10-13 | 2023-04-20 | Board Of Regents, The University Of Texas System | Compositions and methods for modulating mitochondrial function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US20060276477A1 (en) | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| EP1960363B1 (en) | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| EP2327696A1 (en) | 2006-06-26 | 2011-06-01 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
| DE102006050513A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| AU2009225869B2 (en) * | 2008-03-18 | 2014-01-23 | Merck Sharp & Dohme Llc | Substituted 4-hydroxypyrimidine-5-carboxamides |
| DE112009001995A5 (de) * | 2008-08-22 | 2011-09-29 | Inventus Engineering Gmbh | Bewegung dämpfende Vorrichtung |
| WO2010093727A1 (en) | 2009-02-10 | 2010-08-19 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
| CN103068821B (zh) * | 2010-08-13 | 2015-02-25 | 詹森药业有限公司 | 作为脯氨酰羟化酶抑制剂的4-氨基喹唑啉-2-基-1-吡唑-4-羧酸化合物 |
-
2011
- 2011-08-12 CN CN201180039665.8A patent/CN103068821B/zh active Active
- 2011-08-12 US US13/816,747 patent/US8796263B2/en active Active
- 2011-08-12 WO PCT/US2011/047626 patent/WO2012021830A1/en active Application Filing
- 2011-08-12 EP EP11749643.0A patent/EP2603502B1/en active Active
- 2011-08-12 JP JP2013524250A patent/JP5755741B2/ja active Active
- 2011-08-12 AU AU2011289230A patent/AU2011289230B2/en not_active Ceased
-
2013
- 2013-10-22 HK HK13111845.9A patent/HK1184451A1/zh not_active IP Right Cessation
-
2014
- 2014-06-24 US US14/313,892 patent/US9006251B2/en active Active - Reinstated
-
2015
- 2015-03-26 US US14/670,352 patent/US9573940B2/en active Active
-
2017
- 2017-02-17 US US15/436,596 patent/US10246442B2/en active Active - Reinstated
-
2019
- 2019-04-01 US US16/371,400 patent/US10975062B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140309215A1 (en) | 2014-10-16 |
| US9006251B2 (en) | 2015-04-14 |
| US20130143871A1 (en) | 2013-06-06 |
| US9573940B2 (en) | 2017-02-21 |
| AU2011289230A1 (en) | 2013-02-21 |
| CN103068821B (zh) | 2015-02-25 |
| JP5755741B2 (ja) | 2015-07-29 |
| WO2012021830A1 (en) | 2012-02-16 |
| US10975062B2 (en) | 2021-04-13 |
| US10246442B2 (en) | 2019-04-02 |
| JP2013536194A (ja) | 2013-09-19 |
| EP2603502A1 (en) | 2013-06-19 |
| US20170320859A1 (en) | 2017-11-09 |
| CN103068821A (zh) | 2013-04-24 |
| EP2603502B1 (en) | 2014-07-30 |
| AU2011289230B2 (en) | 2014-09-04 |
| US20200095234A1 (en) | 2020-03-26 |
| US8796263B2 (en) | 2014-08-05 |
| US20150197507A1 (en) | 2015-07-16 |
| US20180148435A9 (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223104A1 (zh) | 作為治療劑之精胺酸酶抑制劑 | |
| HK1206743A1 (zh) | 作為 羥化酶抑制劑的 -羥基-異喹啉化合物 | |
| PL2563771T3 (pl) | Związki inhibitora metaloenzymu | |
| ZA201401310B (en) | Polymorphic forms of compounds as prolyl hydroxylase inhibitor,and uses thereof | |
| HK1184451A1 (zh) | 作為脯氨酰羥化酶抑制劑的 -氨基喹唑啉- -基- -吡唑- -羧酸化合物 | |
| HK1198163A1 (zh) | 金屬酶抑制劑化合物 | |
| HK1198651A1 (zh) | 金屬酶抑制劑化合物 | |
| HK1205103A1 (zh) | 金屬酶抑制劑化合物 | |
| EP2584903A4 (en) | NEW HETEROCYCLIC COMPOUNDS AS ERK HEMMER | |
| IL221823A (en) | Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors | |
| HK1190334A1 (zh) | 脯氨酰羥化酶抑制劑 | |
| EP2528926A4 (en) | HEPATITIS C INHIBITOR COMPOUNDS | |
| EP2757884A4 (en) | PYRAZOLOPYRIDYL COMPOUNDS AS AN ALDOSTERONE SYNTHESIS HEMMER | |
| EP2723730A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
| GB201004311D0 (en) | New enzyme inhibitor compounds | |
| EP2638021A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
| EP2632903A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
| EP2632268A4 (en) | NEW CONNECTIONS AS ERK HEMMER | |
| EP2651905A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
| HK1191327A1 (zh) | 作為 抑制劑的氮雜螺環癸酮化合物 | |
| EP2751117A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
| GB201002752D0 (en) | Benzimidazol-2-ones as inhibitors for prolyl endopeptidase | |
| SI2496236T1 (sl) | Prolilhidroksilazni inhibitorji | |
| GB201004308D0 (en) | New inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230810 |